A single podcast appearance may be about to reshape the compounding pharmacy industry’s access to a category of compounds that has been off-limits since 2023.
On February 27, HHS Secretary Robert F. Kennedy Jr. announced plans to reverse an FDA decision that had restricted nearly two dozen peptides from legal compounding. His position on the dispute was clear: the agency moved these compounds to a restricted list without the valid safety signal required to justify the action.
What RFK on peptides signals for compounding pharmacies (and the telehealth companies that rely on them) is a potentially significant shift in formulary access. Here is a breakdown of what was said, what led to it, and what a reversal could mean operationally.
What Did the FDA Restrict and When?
In September 2023, the FDA moved 19 peptides to its Category 2 bulk drug substances list. That designation prohibited compounding pharmacies from legally producing those compounds.
Compounding pharmacy trade groups challenged the FDA’s process almost immediately and argued the agency lacked the safety signal required for Category 2 reclassification. The broader RFK FDA debate reflects ongoing tension between compounding access pathways and the agency’s unapproved drug framework.
When licensed compounding pharmacies lost access to these compounds, patient demand did not disappear. Instead it migrated. A significant portion of current peptide use is sourced from research-grade, non-human-use suppliers/products manufactured without the pharmaceutical oversight, purity standards or exact dosing verification that compounding regulations require. These compounds are labeled explicitly for laboratory research, not human administration.
What Did RFK Jr. Say on Joe Rogan?
The Joe Rogan peptides podcast episode aired on February 27, and brought compounding policy in front of a mainstream audience. Kennedy’s position was straightforward: the FDA acted outside its permitted regulatory grounds when it reclassified these compounds.
The core procedural argument by RFK on peptides centers around the agency’s concerns on efficacy, which are not a valid basis for Category 2 placement under existing compounding law. His stated goal is to restore legal access to approximately 14 of the 19 restricted peptides.
The RFK JR on peptides discussion extended beyond the procedural question. Kennedy argued that restricting legal compounding channels had pushed demand toward unregulated gray market sources, which created a supply chain integrity problem the restrictions were never designed to produce. His position is that the solution is not to suppress demand but to restore a regulated, pharmacy-grade supply chain capable of meeting it responsibly.
How Did the Ban Create a Supply Chain Problem?
The 2023 restrictions did not reduce demand for these compounds. Instead, they redirected it. Joe Rogan talking about peptides with Kennedy put renewed public attention on a dynamic the compounding industry had been managing since the restrictions took effect.
The broader position held by RFK on peptides is that compounding pharmacies represent the only regulated channel capable of meeting this demand responsibly. The arguments made by RFK JR on peptides closely mirror the positions compounding trade groups advanced in legal challenges against the FDA, which cited:
- Lack of publicly available safety data used to justify Category 2 placement
- Absence of a documented safety signal for the majority of restricted compounds
- Patient displacement toward unregulated research chemical sources.
That displacement has real consequences. Research-grade peptide products are not subject to identity testing, potency verification, sterility standards or contamination controls. Patients sourcing these compounds outside a licensed pharmacy have no reliable mechanism to verify what they are receiving meets label claims.
At least some of those challenges have since reached settlement. Research on compounding pharmacy regulation has documented how restricted legal access can create downstream quality and traceability gaps across the compounding supply chain.
What Could Restored Access Mean Operationally?
A formal reversal would allow compounding pharmacies to source these compounds from FDA-inspected API facilities again. For telehealth companies evaluating formulary partnerships, the practical implications include:
- Restored formulary depth for pharmacies previously restricted from producing these compounds
- Verified supply chain sourcing, including regulated API suppliers versus uncontrolled gray market channels
- Formulation traceability consistent with standard compounding compliance documentation
- A pathway for patients currently using research-grade sources to transition to pharmacy-grade compounds prepared under USP standards.
Current RFK FDA signals from the administration point toward a targeted restoration that covers approximately 14 compounds, not a full reversal of the 2023 list. RFK JR on peptides has framed the discussion around access through what he’s called “ethical suppliers” (a standard that licensed compounding pharmacies already meet).
The broader compounding formulary extends well beyond this category. Areas including hormone replacement therapy have continued under established regulatory frameworks throughout this period. Clinical reviews of therapeutic peptides point to continued development potential for several of these compounds independently of their compounding regulatory status.
What Happens Next?
An RFK FDA decision was expected in the weeks following the February 27 broadcast. No specific compound names were disclosed publicly during the episode.
The current posture suggests a defined, targeted restoration for a subset of the compounds restricted in 2023, with RFK JR on peptides signaling that any action will be backed by the FDA’s formal scientific review process.
Frequently Asked Questions
Which peptides did RFK Jr. say would be unrestricted?
Kennedy stated approximately 14 of the 19 restricted compounds are under FDA review for potential removal from the Category 2 list. Specific compound names were not disclosed during the broadcast.
How does the Category 2 designation affect compounding pharmacies?
It prohibits compounding pharmacies from legally producing those compounds. The designation applies specifically to the compounding channel and does not affect commercial pharmaceutical manufacturing.
Why are research-grade peptides considered a supply chain concern? Research-grade peptides are manufactured for laboratory use not human administration. They are not subject to the identity testing, sterility standards, potency verification or contamination controls that apply to pharmacy-compounded medications. Their proliferation as a de facto consumer source is a direct consequence of the 2023 restrictions on legal compounding access.
Does this regulatory change affect all compounding pharmacies equally?
A formal reversal would apply broadly to licensed compounding pharmacies. Operational impact depends on each pharmacy’s existing formulary, licensing scope, and established API supplier relationships.
At Precision Medicine, we serve as a white-label fulfillment partner for DTC telemedicine companies nationwide, holding 48 non-sterile and 47 sterile state licenses, NABP accreditation, and USP 795, 797, and 800 compliance.We monitor regulatory developments closely as part of our evolution as a trusted fulfillment partner. As the landscape evolves, we continue expanding our formulary capabilities to meet the shifting needs of our partners.